. . . . "Melizide"@en . "Glipizide"@en . . "Take 30-60 minutes before breakfast."@en . "Glibetin"@en . . . . . . . . . . "Mindiab"@en . . "Digrin"@en . . "Glipizidum"@en . . "Glidiab"@en . . "Sucrazide"@en . . . . . . . . . . . . . "Glydiazinamide"@en . "Avoid sugar and sugary food."@en . "Glucotrol"@en . . "Glupitel"@en . . . . "The acute oral toxicity was extremely low in all species tested (LD50 greater than 4 g/kg). Overdosage of sulfonylureas including glipizide can produce hypoglycemia."@en . "CP 28,720"@en . "Ozidia"@en . "Glyde"@en . . "Avoid alcohol."@en . . "Suresh Kumar Gidwani, Purushottam Singnurkar, Prashant Kumar Tewari, \"Sustained release pharmaceutical composition containing glipizide and method for producing same.\" U.S. Patent US6270797, issued February, 2000."@en . . "Gluco-rite"@en . "approved"@en . "Glibenese"@en . "Glican"@en . "For use as an adjunct to diet for the control of hyperglycemia and its associated symptomatology in patients with non-insulin-dependent diabetes mellitus (NIDDM; type II), formerly known as maturity-onset diabetes, after an adequate trial of dietary therapy has proved unsatisfactory."@en . . . . . . "N-{4-[beta-(5-methylpyrazine-2-carboxamido)ethyl]benzenesulphonyl}-n'-cyclohexylurea"@en . . . . "Humans and other mammals"@en . . . "Glupizide"@en . . . . . . . . . . . "The primary metabolites are inactive hydroxylation products and polar conjugates and are excreted mainly in the urine."@en . "K 4024"@en . . . . . . . . . . . . "Gastrointestinal absorption is uniform, rapid, and essentially complete."@en . . . "Minodiab"@en . . . . . . "98-99%, primarily to albumin."@en . "Glucolip"@en . . "Glucozide"@en . "Minidab"@en . . "Napizide"@en . . "Aldiab"@en . . . "Glipid"@en . . "CP-28,720"@en . . . . . . . . . . . . . . "Dipazide"@en . . . . " "@en . . . . . . . . . . . . "* 11 L"@en . . . . . . . . . . . . "1-Cyclohexyl-3-({p-[2-(5-methylpyrazinecarboxamido)ethyl]phenyl}sulfonyl)urea"@en . . . . "Sulfonylureas likely bind to ATP-sensitive potassium-channel receptors on the pancreatic cell surface, reducing potassium conductance and causing depolarization of the membrane. Depolarization stimulates calcium ion influx through voltage-sensitive calcium channels, raising intracellular concentrations of calcium ions, which induces the secretion, or exocytosis, of insulin."@en . . "CP 28720"@en . . . . "Glipizida"@en . . "An oral hypoglycemic agent which is rapidly absorbed and completely metabolized. [PubChem]"@en . . . . "29094-61-9"@en . "Minidiab"@en . "2-5 hours"@en . . . . . . . . . . .